REMARKS

The above amendment to the specification has been made to be in compliance with CFR §§1.821-1.825. No new matter is added by this amendment.

CONCLUSION

Attached hereto is a marked-up version of the changes made to the specification by the current amentment. The attached page is captioned "**Version with markings to show changes made**."

In the unlikely event that the transmittal letter is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our **Deposit Account No. 03-1952**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 1, 2002

By: 

Catherine M. Polizzi
Registration No. 40,130

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5876
Facsimile: (650) 494-0792

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification

[0075] For scFv fragments, light and/or heavy chain variable regions are linked using a short linking peptide. Bird et al. (1998) Science 242:423-426. An example of a linking peptide is $(GGGGS)_3$ (SEQ ID NO:5), which bridges approximately 3.5 nm between the carboxy terminus of one variable region and the amino terminus of the other variable region. Linkers of other sequences have been designed and used. Bird et al. (1988). Usually the linkers are selected to have little to no immunogenicity. For asymmetrical linkers, the scFvs can be assembled in any order. Generally, the entire variable regions are included in the scFv, which may be produced either recombinantly or synthetically.